Key result
Trientine shows potential to restore myocardial copper homeostasis and reverse remodeling in hypertrophic cardiomyopathy.
Why the study?
Trientine demonstrates beneficial effects in hypertrophic cardiomyopathy, but its mechanisms for improving the condition remain unclear.
Does trientine improve cardiac structure and function in hypertrophic cardiomyopathy?
Does trientine improve cardiac structure and function in hypertrophic cardiomyopathy?
Trientine shows mechanistic promise for treating hypertrophic cardiomyopathy by targeting underlying myocardial copper deficiencies.
Answers are grounded in this paper and cite their sources.
Trientine may warrant evaluation in hypertrophic cardiomyopathy; leaves open confirmation of benefit in large randomized trials.
Abnormality in myocardial copper homeostasis is believed to contribute to the development of cardiomyopathy. Trientine, a copper-chelating drug used in the management of patients with Wilson's disease, demonstrates beneficial effects in patients with hypertrophic cardiomyopathy. This review aims to present the updated development of the roles of trientine in hypertrophic cardiomyopathy. The drug has been demonstrated in animal studies to restore myocardial intracellular copper content. However, its mechanisms for improving the medical condition remain unclear. Thus, comprehending its mechanistic aspects in cardiomyopathy is crucial and could help to expedite future research.
No takes yet. Share an insight, caveat, or question.
Ramli et al. (2022) conducted a review in Hypertrophic cardiomyopathy and cardiac hypertrophy. Trientine was evaluated. Trientine demonstrates potential to restore myocardial copper homeostasis, which may improve mitochondrial bioenergetics and reverse cardiac remodeling in hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: